Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cognition Therapeutics Inc (NQ: CGTX ) 0.4709 -0.0012 (-0.25%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 238,738 Open 0.4740 Bid (Size) 0.4700 (30) Ask (Size) 0.4930 (3) Prev. Close 0.4721 Today's Range 0.4706 - 0.4758 52wk Range 0.3400 - 2.950 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD October 31, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD October 29, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Performance YTD -75.73% -75.73% 1 Month +8.25% +8.25% 3 Month -28.23% -28.23% 6 Month -76.34% -76.34% 1 Year -55.58% -55.58% More News Read More Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD October 23, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB) October 22, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference October 02, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia October 01, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Monday's After-Market Session September 30, 2024 Via Benzinga Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences September 03, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease August 22, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q2 2024 August 08, 2024 Via InvestorPlace Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update August 08, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Cognition Therapeutics to Report Second Quarter 2024 Financial Results August 05, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday July 30, 2024 Via InvestorPlace Dow Edges Lower; Ventyx Biosciences Shares Plummet July 29, 2024 Via Benzinga Topics Stocks Exposures US Equities Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session July 29, 2024 Via Benzinga Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump July 29, 2024 Via Benzinga Exposures Fossil Fuels Tivic Health Systems (TIVC) Stock Pops Another 39% July 29, 2024 Via InvestorPlace Cognition Therapeutics Stock Tumbles On Mixed Data From Mid-Stage Alzheimer's Study July 29, 2024 Via Benzinga Why Is NLS Pharmaceutics (NLSP) Stock Up 48% Today? July 29, 2024 Via InvestorPlace Why Is Cognition Therapeutics (CGTX) Stock Down 33% Today? July 29, 2024 Via InvestorPlace Nasdaq Gains 1%; McDonald's Posts Downbeat Results July 29, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday July 29, 2024 Via InvestorPlace Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients July 29, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket July 29, 2024 Via Benzinga Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024 July 26, 2024 From Cognition Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
